Lamotrigine Tablet, Film Coated, Extended Release
Product Images NDC 70518-4442

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 70518-4442). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

100 mg Tab (100mg Picture)

100 mg Tab (100mg Picture)
FDA Label Image

200 mg Tab (200mg Picture)

200 mg Tab (200mg Picture)
FDA Label Image

250 mg Tab (250mg Picture)

250 mg Tab (250mg Picture)
FDA Label Image

25 mg Tab (25mg Picture)

25 mg Tab (25mg Picture)
FDA Label Image

300 mg Tab (300mg Picture)

300 mg Tab (300mg Picture)
FDA Label Image

50 mg Tab (50mg Picture)

50 mg Tab (50mg Picture)
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
This is a description of Lamotrigine 50 mg extended-release tablets in a pack of 30 tablets. The tablets are round and green in color. The manufacturer is Camber Pharma, Inc, and the repackaging was done by RemedyRepack Inc. The medication should be stored at 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F). Child-proof packaging is advised for safety.*
FDA Label Image

Figure 1. Proportion Of Patients By Responder Rate For Lamotrigine And Placebo Group (primary Generalized Tonic-clonic Seizures Study) (Figure 1)

Figure 1. Proportion Of Patients By Responder Rate For Lamotrigine And Placebo Group (primary Generalized Tonic-clonic Seizures Study) (Figure 1)
This text appears to show a comparison between a placebo and Lamotrigine regarding responder rates, improvement, and worsening. The data includes the number of patients in each group and a graph displaying the percentages of patients that fall into different response categories.*
FDA Label Image

Figure 2. Proportion Of Patients By Responder Rate For Lamotrigine And Placebo Group (partial-onset Seizure Study) (Figure 2)

Figure 2. Proportion Of Patients By Responder Rate For Lamotrigine And Placebo Group (partial-onset Seizure Study) (Figure 2)
This data shows the responder rate in terms of improvement and worsening for lamotrigine compared to a placebo. The responder rate for improvement with lamotrigine is 100% for 4 points and 5% for worsening by 50%. The table also includes the percentage of patients for different categories, such as 60, 50, 20, 30, 20, and 10. The sample sizes for placebo and lamotrigine are 120 and 116, respectively.*
FDA Label Image

Chemical Structure (Graphic 01)

Chemical Structure (Graphic 01)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.